WT1 Peptide-Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases

This publication has 27 references indexed in Scilit:

• Development of HLA‐A2402/K^b transgenic mice
  International Journal of Cancer, 2002
• Humoral immune responses against Wilms tumor gene WT1product in patients with hematopoietic malignancies
  Blood, 2002
• Very low frequencies of human normal CD34⁺ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells
  British Journal of Haematology, 2002
• A HER2/NEU-derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes
  International Journal of Cancer, 2000
• Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
  Blood, 2000
• Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
  Blood, 2000
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
  Blood, 1994
• Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms Tumor
  Science, 1990
• Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
  Nature, 1990
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
  Cell, 1990